Review Article
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
Table 2
Pharmacologic properties of direct-acting anti-HCV agents in clinical development, modified by Liang and Ghany [
71].
| Property | NS3-4A protease inhibitors |
| Efficacy | High | Genotypic coverage | Narrow (second generation drugs have broader coverage) | Probability of drug resistance | High | Side effects | Substantial | Drug-drug interactions | Substantial |
|
|